Stock PSTX POSEIDA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. Poseida Therapeutics, Inc.

Equities

PSTX

US73730P1084

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
2.99 USD +3.10% Intraday chart for Poseida Therapeutics, Inc. +0.67% -11.01%
May. 14 Poseida Therapeutics Q1 Net Loss Narrows, Revenue Rises MT
May. 14 Earnings Flash (PSTX) POSEIDA THERAPEUTICS Reports Q1 Revenue $28.1M MT

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Piper Sandler Adjusts Price Target on Poseida Therapeutics to $10 From $8, Maintains Overweight Rating
MT
HC Wainwright Adjusts Price Target on Poseida Therapeutics to $20 From $15, Keeps Buy Rating
MT
HC Wainwright Initiates Poseida Therapeutics With Buy and $15 Price Target
MT
Piper Sandler Adjusts Price Target on Poseida Therapeutics to $11 From $9, Reiterates Overweight Rating
MT
Piper Sandler Adjusts Price Target on Poseida Therapeutics to $9 From $19, Maintains Overweight Rating
MT
Cantor Fitzgerald Starts Poseida Therapeutics at Overweight with $24 Price Target
MT
POSEIDA THERAPEUTICS : Piper Sandler Adjusts Poseida Therapeutics PT to $19 From $17, Maintains Overweight Rating
MT
POSEIDA THERAPEUTICS : BTIG Initiates Poseida Therapeutics at Buy Rating With $40 Price Target
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PSTX Stock
  4. News Poseida Therapeutics, Inc.
  5. Analyst Reco.